Orforglipron lowered A1C and body weight more than oral semaglutide 25 mg at 52 weeks, but the estimate comes from an indirect comparison.

Brian Smith, PharmD, explains how direct-to-consumer GLP-1 pathways broaden initial access but endanger long-term patient adherence.

The analysis is not a head-to-head trial, and the weight loss gap reached statistical significance under 1 of 2 estimands.

A claims analysis of 2031 patients aged 10 to 17 years found that nutrition counseling was infrequent and often began months after treatment started.

Medicaid coverage of obesity-labeled GLP-1 receptor agonists may substitute for, rather than simply add to, diabetes-labeled use, a new study finds.

With obesity, muscle loss, and sleep disorders so prominent in postmenopause, providers are now looking into further expansion of GLP-1 use.

Research shows that cost-plus pricing can lower drug costs dramatically, depending on where in the supply chain the markup is applied.

Medicaid and Part D low-income subsidy enrollment narrowed some gaps, but much of the disparity occurred within the same plans.